Is this method safe
Semaglutide 2.4mg (GLP-1 Agonist): Proven GLP-1 effects (appetite suppression, gastric emptying) Already FDA-approved as Wegovy Established safety profile Cagrilintide 2.4mg (Amylin Analog): Mimics amylin, a hormone co-secreted with insulin Slows gastric emptying through different pathway than GLP-1 Reduces appetite through hindbrain (not hypothalamus) Improves postprandial glucose The Advantage: Leverages proven semaglutide efficacy and safety, adds complementary amylin effects
Czechia Greater than 99.8 % purity confirmed by COA Assay content verified at 50.7 mg Endotoxin level below 0.001 EU/mg No detectable heavy metals or microbial contamination High-purity peptide for controlled laboratory research For research use only not for human or veterinary use For laboratory research only
Circulation 142:12051218 Hernandez AF, Green JB, Janmohamed S, DAgostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S (2018) Harmony Outcomes committees and investigators